Key result
Elevated admission tenascin-C in acute STEMI predicts LV remodeling and MACE at 6 months.
Why the study?
The clinical implications of serum tenascin-C levels in predicting left ventricular remodeling and prognosis after acute myocardial infarction treated with thrombolytic therapy were unclear.
Does serum tenascin-C level predict left ventricular remodeling and MACE in patients with acute STEMI treated with streptokinase?
Case-Control (n=80)
Does serum tenascin-C level predict left ventricular remodeling and MACE in patients with acute STEMI treated with streptokinase?
Absolute Event Rate: 57.49% vs 34%
p-value: p=0.0001
Elevated serum tenascin-C levels on admission may predict subsequent left ventricular remodeling and major adverse cardiac events in patients with acute STEMI treated with streptokinase.
May support tenascin-C for STEMI risk stratification; hypothesis-generating and should not yet change practice.
We investigated clinical implications of serum tenascin-C (TN-C) levels in patients with acute myocardial infarction (AMI) treated with thrombolytic therapy Serum TN-C levels were measured by ELISA in 60 cases presented with acute STEMI and 20 normal controls. The mean serum TN-C level of AMI patients on admission (57.5 ng/ml) was significantly higher than that of controls (57.49 ± 19.89 ng/ml vs. 34 ± 3.02 ng/ml; p=0.0001), follow-up examination (mean: 6 months) revealed that 17 of 60 AMI (28%) patients showed left ventricular (LV) remodeling (20% end-diastolic volume increase), and in 6 (10%), major adverse cardiac events (MACE) were detected. By receiver-operating characteristic (ROC) analysis, TN-C levels clearly discriminated prediction of LV remodeling and MACE compared with other variables including creatine kinase-MB, and LV function. Diabetes and TN-C were correlated with MACE in our study. The findings suggest that serum TN-C levels might be useful in predicting LV remodeling and prognosis after AMI.
No takes yet. Share an insight, caveat, or question.
TM et al. (2016) conducted a case-control in Acute myocardial infarction (STEMI) (n=80). Serum tenascin-C (TN-C) levels vs. Normal controls was evaluated on Serum TN-C level on admission (p=0.0001). Serum tenascin-C levels on admission were significantly higher in acute STEMI patients than controls (57.49 vs 34 ng/ml; p=0.0001) and predicted left ventricular remodeling and MACE at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: